BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioMarin Pharma (BMRN) Tops Q1 EPS by 39c, Revs Beat; Trims FY Rev Outlook
April 29, 2020 4:03 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.44, $0.39 better than the analyst estimate of $0.05. Revenue for the quarter came in at $502.1 million versus the consensus estimate of $468.77 million.
GUIDANCE:
BioMarin Pharma sees FY2020 revenue of $1.85-1.95 billion, versus prior of... More
